Announcements Trials
Browse Landscape

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 3Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

ravulizumab 3Tacrolimus 3Pyridostigmine Bromide 3Prednisone 3Mycophenolic Acid 3Data Collection 3Azathioprine 3efgartigimod alfa 2Steroids 2Diagnostic Self Evaluation 2Blood Specimen Collection 2rozanolixizumab 1Thymectomy 1Therapeutics 1Telemedicine 1Neurofeedback 1Methylprednisolone 1Methotrexate 1Immunosuppressive Agents 1Immunoglobulins, Intravenous 1Genotype 1Cyclosporine 1Cyclophosphamide 1Biomarkers 1Alleles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Myasthenia Gravis × ravulizumab × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔